Catalyst Wire Dossier Catalyst Wire Dossier

Eylea (aflibercept)

aflibercept · Regeneron Pharmaceuticals, Inc.
Drug timelines are a Plus or Pro feature.

8 regulatory and trial events tracked for Eylea (aflibercept), covering 2015-12-29 to 2026-03-30. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema [Phase 1, Phase 2]

See pricing